Document is current
Any future updates will be listed below
-
Authors
Hoskins, Emily L.
Vella, Raven
Reeser, Julie W.
Wing, Michele R.
Samorodnitsky, Eric
Turkoglu, Altan
Stein, Leah
Breuning, Elizabeth
Risch, Zachary A.
Hernandez-Sanchez, Wilnelly M.
Yu, Lianbo
Churchman, Michelle
Single, Nancy
Chahoud, Jad
Jimeno, Antonio
Cavnar, Michael J.
Reilley, Matthew
Scaife, Courtney
Nepple, Kenneth G.
Phan, Minh
Schneider, Bryan
Edge, Stephen
Salhia, Bodour
Leiser, Aliza
Wise-Draper, Trisha M.
Wendt, Michael K.
Roychowdhury, Sameek
-
Funding
Funding for this research was provided by:
Pelotonia
National Cancer Institute (UH2CA262220, UH2CA262220, UH2CA262220, UH2CA262220, UH2CA262220)
Gateway for Cancer Research
- License Information
-
More Information
Article History
Received: 17 October 2024
Accepted: 21 March 2025
First Online: 3 July 2025
Competing interests
: S.R. participated in Advisory Boards for Incyte Corporation (2017, 2023), AbbVie, Inc. (2017), QED Therapeutics (2018, 2019), Bayer (2020), Seagen (2023), Tyra Biosciences (2023), Taiho (2024). [Health care companies) (<10,000 USD). S.R. received honoraria from IDT Integrated DNA Technologies (2017), Illumina (2018). [Technology companies]. S.R. received consulting fees from QED Therapeutics (2018, 2019) and Merck (2019). [Health care companies] (<10,000 USD). S.R. received travel reimbursement from Incyte Corporation (2019)(Less than 999 USD). T.W.D. Consulting/Ad Board; Caris Life Sciences, NEED Inc, Merck & Co., EMD Serono, Adlai Nortye, Genmab, Replimmune; Stock: High EnrollClinical trial funding: Merck & Co., BMS, Janssen, AstraZeneca, Tesaro/GSK
